CMPX Compass Therapeutics, Inc.

CIK 0001738021 20 ready 8-Ks latest May 5, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 20

Latest filing May 5, 2026, 7:59 PM ET

Top materiality 0.85

Event mix other_material ×8 · earnings ×7 · other ×2

Sentiment 7 pos · 0 neg · 13 neu

Executive change recent →

Recent 8-K filings for CMPX

Highest-materiality recent filing

Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned

May 5, 2026, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.
Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.

Read filing →

May 5, 2026, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned

Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.
April 27, 2026, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission

Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).
March 5, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April

Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.
January 6, 2026, 6:59 PM ET other material materiality 0.65 positive item 2.02 item 8.01 item 9.01

Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO

Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.
November 5, 2025, 6:59 PM ET other material materiality 0.65 positive item 2.02 item 9.01

Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026

Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).
August 13, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants

Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.
August 11, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026

Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.
June 12, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Compass Therapeutics annual meeting elects three directors, ratifies auditor

Carl L. Gordon, Philip J. Ferneau, and James P. Boylan elected as Class II directors with 80.7M, 58.3M, and 83.6M votes for, respectively.
May 8, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M

Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.
April 1, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)

ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.
February 27, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025

Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).
January 8, 2025, 6:59 PM ET other material materiality 0.55 neutral item 2.02 item 8.01 item 9.01

Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025

Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.
December 10, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01

Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO

Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.
November 12, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M

Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.
August 12, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025

Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.
June 17, 2024, 7:59 PM ET other materiality 0.00 neutral item 5.07

Compass Therapeutics shareholders elect Chiniara and Gray, ratify auditor

Ellen V. Chiniara received 76,766,213 for and 23,754,485 withheld as director.
May 28, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO

Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.
May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009

Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.
April 25, 2024, 7:59 PM ET regulatory materiality 0.60 positive item 7.01 item 9.01

FDA grants Fast Track Designation for Compass's CTX-009 in biliary tract cancer

FDA Fast Track Designation for CTX-009 (bispecific DLL4/VEGF-A antibody) + paclitaxel in previously treated metastatic/locally advanced biliary tract cancer.
March 21, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024

Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.

Executive changes

Role change

Thomas Schuetz

President and Chief Executive Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.

Departed

Vered Bisker-Leib

Chief Executive Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2024-05-28
Successor: Thomas Schuetz
Filed: May 28, 2024, 7:59 PM ET

On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.68 · Most common event other_material

7 positive 0 negative 13 neutral

source · CMPX on sec.gov